European Society for Medical Oncology Asia Congress 2025 (ESMO Asia 2025)

Singapore 05 December 2025 - 07 December 2025

177Lu-Dotatate boosts PFS in Asian patients with advanced GEP-NETs

04 Feb 2026 by

Peptide receptor radionuclide therapy (PRRT) with lutetium-177 (¹⁷⁷Lu)-Dotatate significantly improved progression-free survival (PFS) among Asian patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), according to the LUMINET-1 study presented at ESMO Asia 2025.

04 Feb 2026

Durvalumab plus FLOT improves survival in Asians with G/GEJ adenocarcinoma

30 Jan 2026 by

Adding durvalumab to 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) improves event-free survival (EFS) and overall survival (OS) in Asian patients with resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, according to a subgroup analysis of the phase III MATTERHORN trial presented at ESMO Asia 2025.

30 Jan 2026

$Liposomal irinotecan plus nimotuzumab takes on immunotherapy-refractory NPC$ $Liposomal irinotecan plus nimotuzumab takes on immunotherapy-refractory NPC$

Liposomal irinotecan plus nimotuzumab takes on immunotherapy-refractory NPC

21 Jan 2026 by

In patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) refractory to immune checkpoint inhibitor (ICI) therapy, the combination of liposomal irinotecan plus nimotuzumab yields meaningful clinical activity while having favourable tolerability, as shown in a phase II study.

21 Jan 2026

Low-dose olanzapine as good as megestrol acetate for cancer anorexia–cachexia syndrome

20 Jan 2026 by

For vulnerable cancer patients undergoing chemotherapy, treatment with low-dose olanzapine works just as well as megestrol acetate in terms of promoting appetite and weight gain, as shown in a study.

20 Jan 2026

Zongertinib shows promise in Asians with advanced HER2-mutant NSCLC

18 Jan 2026 by

Treatment with zongertinib in Asian patients with advanced HER2-mutant nonsmall cell lung cancer (NSCLC), who have received prior systemic therapy, delivers robust efficacy and elicits an acceptable safety profile, consistent with the overall global analysis, reports a China study.